Dr. Tariq Zia, MD Internal Medicine - Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 455 School St, Suite 22, Tomball, TX 77375 Phone: 281-357-1200 Fax: 281-357-1010 |
News Archive
This past summer saw a revolution in melanoma therapy. Patients whose melanoma lesions contain a mutation in the BRAF gene were successfully treated with a BRAF-specific inhibitor, PLX4032. Reports of the drug trial described shrinking tumors and improved health. Yet seven months after therapy began the tumors returned and resumed growing. Now, scientists at The Wistar Institute explain why: the tumor learns to signal around the blocked gene by adjusting its molecular wiring.
Advanced Life Sciences Holdings, Inc. (Nasdaq: ADLS), today announced positive results from Trial CL-05, the second of two pivotal phase III clinical trials designed to assess the safety and effectiveness of cethromycin, a novel once-a-day oral antibiotic for the treatment of mild-to-moderate community acquired pneumonia (CAP), the sixth leading cause of death in the United States.
A research team from Wayne State University has received a $1.85 million grant from the National Institute of General Medical Sciences of the National Institutes of Health for the project "Mechanisms of Non-Shine-Dalgarno Translation Initiation."
Amylin Pharmaceuticals, Inc. and Alkermes plc today announced results from the long-term extension of the DURATION-1 study, which showed that BYDUREON (exenatide extended-release for injectable suspension), the first and only once-weekly treatment for type 2 diabetes, was associated with clinically significant and sustained improvements in glycemic control during four years of treatment in adults with type 2 diabetes.
› Verified 3 days ago